Drug intelligence / Profile preview

acyline + dutasteride + testosterone

Development stage: Phase 2
Lead developer: University of Washington
Modality: Small Molecules
Administration: Subcutaneous, Oral, Intramuscular

Overview

A combination of acyline (a GnRH antagonist), dutasteride (a 5α-reductase inhibitor), and testosterone that has been studied for potential applications in male contraception and hormone replacement therapy. The combination works by suppressing gonadotropin secretion (acyline), inhibiting the conversion of testosterone to dihydrotestosterone (dutasteride), while providing androgenic effects (testosterone). Studies have shown this combination can significantly reduce intratesticular testosterone levels, affect germ cell populations, and potentially improve insulin sensitivity and body composition.

Targets

SRD5A (Steroid 5-alpha-reductase)AR (Adrenergic receptors)GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on acyline + dutasteride + testosterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acyline + dutasteride + testosterone.